The Global Drug sales of Xolair stood at USD 3,780.79 Millions in 2022
The indicator recorded a historical growth (CAGR) of6.22% between 2019 to 2022 and is expected to grow by ...
GlobalData projects the indicator to decline at a CAGR of...
Omalizumab (Xolair) is a recombinant DNA-derived humanized IgG1-kappa monoclonal antibody. It is formulated as powder for solution and solution for subcutaneous route of administration.
Mechanism of Action
Xolair is a recombinant DNA-derived humanized monoclonal antibody, binds to the C epsilon3 domain of immunoglobulin E (IgE) and forms complexes that inhibit the immune system's response to allergens by averting IgE-mediated inflammatory changes. Xolair inhibits the binding of IgE to the high-affinity IgE receptor (Fc and RI) on the surface of mast cells and basophils. Reduction in surface-bound IgE on Fc and RI-bearing cells limits the degree of release of mediators of the allergic response. Treatment with xolair also reduces the number of Fc and RI receptors on basophils in atopic patients.
Xolair Overview
Xolair is marketed for the treatment of several indications in Dermatology, Ear Nose Throat Disorders, Genito Urinary System and Sex Hormones, Immunology, Ophthalmology, and Respiratory therapy areas.
Xolair is a humanized therapeutic antibody for the treat treatment of asthma, chronic idiopathic urticaria and the first approved therapy designed to target the antibody IgE, a key underlying cause of the symptoms of allergy related asthma. Xolair is indicated for adults and adolescents (12 years of age and above) with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids, to treat moderate to severe persistent asthma in children 6 to 11 years of age who have had a positive skin test or in vitro reactivity to an airborne allergen and have symptoms that are inadequately controlled with inhaled corticosteroids, as an add-on therapy for the treatment of chronic spontaneous urticaria in adult and adolescent (12 years and above) patients with inadequate response to H1 antihistamine treatment, and for the treatment of seasonal allergic rhinitis. Xolair is indicated for add-on maintenance treatment of nasal polyps in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.
Xolair was first approved in 2002 and is sold globally including the US, the UK, Australia, Germany, and Japan by several pharma giants including F. Hoffmann-La Roche Ltd, and Novartis AG. Xolair drug sales recorded a mid-single digit Year on Year growth in 2022. Xolair drug sales include the historical sales that are derived from company financial reports, and consensus forecasts are calculated based on company-specific broker reports as well as GlobalData’s proprietary methodology.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer